# Chemotherapy for Participants With Lymphoma

> **NCT00436280** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Lymphoma, Large Cell, Diffuse

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** gemcitabine
- **DRUG:** rituximab
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00436280
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-11
- **Final completion:** 2012-11
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436280, "Chemotherapy for Participants With Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00436280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*